Trial Outcomes & Findings for Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene (NCT NCT05125237)
NCT ID: NCT05125237
Last Updated: 2025-11-06
Results Overview
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Recruitment status
COMPLETED
Target enrollment
155963 participants
Primary outcome timeframe
Median follow up times: 1) 119 days (exp), 111 days (ref) 2) 859 days (exp), 852 days (ref) 3) 333 days (exp), 286 days (ref) 4) 120 days (exp), 111 days (ref)
Results posted on
2025-11-06
Participant Flow
Participant milestones
| Measure |
Amiloride
Exposure group
Amiloride: Amiloride claim is used as the exposure group.
|
Triamterene
Reference group
Triamterene: Triamterene claim is used as the reference group.
|
|---|---|---|
|
Overall Study
STARTED
|
7476
|
148487
|
|
Overall Study
COMPLETED
|
7305
|
7305
|
|
Overall Study
NOT COMPLETED
|
171
|
141182
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene
Baseline characteristics by cohort
| Measure |
Amiloride
n=7305 Participants
Exposure group
Amiloride: Amiloride claim is used as the exposure group.
|
Triamterene
n=7305 Participants
Reference group
Triamterene: Triamterene claim is used as the reference group.
|
Total
n=14610 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Race/Ethnicity, Customized
White
|
6019 Participants
n=49 Participants
|
6054 Participants
n=50 Participants
|
12073 Participants
n=50 Participants
|
|
Sex: Female, Male
Female
|
4253 Participants
n=49 Participants
|
4219 Participants
n=50 Participants
|
8472 Participants
n=50 Participants
|
|
Sex: Female, Male
Male
|
3052 Participants
n=49 Participants
|
3086 Participants
n=50 Participants
|
6138 Participants
n=50 Participants
|
|
Age, Categorical
<=18 years
|
0 Participants
n=49 Participants
|
0 Participants
n=50 Participants
|
0 Participants
n=50 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=49 Participants
|
0 Participants
n=50 Participants
|
0 Participants
n=50 Participants
|
|
Age, Categorical
>=65 years
|
7305 Participants
n=49 Participants
|
7305 Participants
n=50 Participants
|
14610 Participants
n=50 Participants
|
|
Age, Continuous
|
74.06 years
STANDARD_DEVIATION 6.61 • n=49 Participants
|
74.22 years
STANDARD_DEVIATION 6.77 • n=50 Participants
|
74.14 years
STANDARD_DEVIATION 6.69 • n=50 Participants
|
|
Race/Ethnicity, Customized
Black
|
825 Participants
n=49 Participants
|
782 Participants
n=50 Participants
|
1607 Participants
n=50 Participants
|
|
Race/Ethnicity, Customized
Asian
|
123 Participants
n=49 Participants
|
120 Participants
n=50 Participants
|
243 Participants
n=50 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
126 Participants
n=49 Participants
|
135 Participants
n=50 Participants
|
261 Participants
n=50 Participants
|
|
Race/Ethnicity, Customized
Native American
|
23 Participants
n=49 Participants
|
21 Participants
n=50 Participants
|
44 Participants
n=50 Participants
|
|
Race/Ethnicity, Customized
Other
|
124 Participants
n=49 Participants
|
124 Participants
n=50 Participants
|
248 Participants
n=50 Participants
|
|
Race/Ethnicity, Customized
Unknown
|
65 Participants
n=49 Participants
|
69 Participants
n=50 Participants
|
134 Participants
n=50 Participants
|
|
Dementia risk factors
Diabetes
|
5784 Participants
n=49 Participants
|
5819 Participants
n=50 Participants
|
11603 Participants
n=50 Participants
|
|
Dementia risk factors
Obesity
|
1979 Participants
n=49 Participants
|
1961 Participants
n=50 Participants
|
3940 Participants
n=50 Participants
|
|
Dementia risk factors
Coronary artery disease
|
3087 Participants
n=49 Participants
|
3182 Participants
n=50 Participants
|
6269 Participants
n=50 Participants
|
|
Dementia risk factors
Depression
|
1168 Participants
n=49 Participants
|
1130 Participants
n=50 Participants
|
2298 Participants
n=50 Participants
|
|
Dementia risk factors
Anxiety
|
1104 Participants
n=49 Participants
|
1108 Participants
n=50 Participants
|
2212 Participants
n=50 Participants
|
|
Dementia risk factors
Bipolar disorder
|
121 Participants
n=49 Participants
|
143 Participants
n=50 Participants
|
264 Participants
n=50 Participants
|
|
Dementia risk factors
Schizophrenia
|
42 Participants
n=49 Participants
|
53 Participants
n=50 Participants
|
95 Participants
n=50 Participants
|
PRIMARY outcome
Timeframe: Median follow up times: 1) 119 days (exp), 111 days (ref) 2) 859 days (exp), 852 days (ref) 3) 333 days (exp), 286 days (ref) 4) 120 days (exp), 111 days (ref)Population: Study cohort after 1:1 propensity score matching
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Outcome measures
| Measure |
Amiloride
n=7305 Participants
Exposure group
Amiloride: Amiloride claim is used as the exposure group.
|
Triamterene
n=7305 Participants
Reference group
Triamterene: Triamterene claim is used as the reference group.
|
|---|---|---|
|
Time to Dementia Onset
Analysis 2
|
20.9 Incidence rate per 1000 person year
Interval 17.5 to 24.8
|
21.5 Incidence rate per 1000 person year
Interval 18.0 to 25.4
|
|
Time to Dementia Onset
Analysis 3
|
12.2 Incidence rate per 1000 person year
Interval 9.2 to 16.0
|
17.4 Incidence rate per 1000 person year
Interval 13.6 to 21.9
|
|
Time to Dementia Onset
Analysis 4
|
2.4 Incidence rate per 1000 person year
Interval 1.4 to 3.8
|
4.3 Incidence rate per 1000 person year
Interval 2.8 to 6.3
|
|
Time to Dementia Onset
Analysis 1
|
12.6 Incidence rate per 1000 person year
Interval 10.1 to 15.6
|
14.8 Incidence rate per 1000 person year
Interval 11.9 to 18.2
|
Adverse Events
Amiloride
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Triamterene
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place